Clinical trials: Metastatic Colorectal Cancer, completed
Colorectal Cancer Metastatic, Thromboembolism
TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer (mCRC) who are scheduled to receive systemic cancer therapy have an increased risk for venous thromboembolic (VTE) events compared with the general population.
- Trial name
- PROTINCOL (NCT05625932)
- Testing
- Tinzaparin
- Where
- 35 sites in Spain
- Volunteers
- 232 people
- Sponsor
- Galician Research Group on Digestive Tumors
Colorectal Cancer, Metastatic Cancer
Gene Expression Profiling in Normal Tissue and Tumor Tissue From Patients With Colon Cancer That Has Spread to the Liver, Lungs, or Peritoneum
RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00896753
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer (CRC)
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer
- Trial name
- NCT00851045
- Testing
- Irinotecan, 5-Fluorouracil (bolus), 5-Fluorouracil (infusional)
- Where
- 15 sites in United States, Argentina and 1 more
- Volunteers
- 17 people
- Sponsor
- Bristol-Myers Squibb
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing…
- Conditions
- Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal
- Trial name
- NCT04426669
- Testing
- Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Intima Bioscience, Inc.
Colorectal Cancer
A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum
This expanded access study will assess the efficacy and safety of intravenous (IV) bevacizumab in combination with chemotherapy regimens as first-line treatment of metastatic cancer of the colon or rectum.
- Trial name
- NCT02582970
- Testing
- 5-Fluorouracil, Bevacizumab, Irinotecan
- Where
- 8 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors.
- Trial name
- FLAGSHP-1 (NCT04670679)
- Testing
- ERAS-601, Cetuximab, Pembrolizumab
- Where
- 14 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Erasca, Inc.
Metastatic Colorectal Cancer
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final…
- Trial name
- NCT01134640
- Where
- 15 sites in Taiwan
- Volunteers
- 286 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Liver Metastasis
Stereotactic Body Radiation Therapy (SBRT) in Liver Metastasis (COLD 3)
This study is designed to see whether stereotactic body radiation therapy (SBRT) can reduce tumour size, slow progression of the disease, prolong life and improve quality of life.
- Trial name
- NCT00914615
- Testing
- Stereotactic Body Radiation
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer
A Reversal in the Vascularity of Metastatic Liver Tumors From Colorectal Cancer After the Cessation of Anti-VEGF Therapy
Objective: To assess the effect of bevacizumab on tumor vessels, and the reversibility of the effect, using contrast-enhanced ultrasonography (CEUS) and histology in patients with metastatic liver tumors derived from colorectal…
- Trial name
- NCT01591109
- Volunteers
- 20 people
- Sponsor
- NHO - Matsumoto Medical Center
Colorectal Neoplasms
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.
- Trial name
- NCT00077987
- Testing
- SU011248
- Volunteers
- 84 people
- Sponsor
- Pfizer
Untreated Metastatic Colorectal Cancer
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
This was a blinded, randomized, placebo-controlled Phase 2 multicenter study evaluating the efficacy and tolerability of veliparib plus irinotecan, fluorouracil, and leucovorin chemotherapy regimen (FOLFIRI) compared to placebo…
- Trial name
- NCT02305758
- Testing
- Veliparib, Modified FOLFIRI, FOLFIRI
- Volunteers
- 130 people
- Sponsor
- AbbVie
Breast Cancer, Colorectal Cancer
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have…
- Conditions
- Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00004604
- Testing
- CEA RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
A study of Avastin (bevacizumab) in combination chemotherapy in patients with metastatic cancer of the colon or rectum. The anticipated time on study treatment is until disease progression.
- Trial name
- NCT01131078
- Testing
- Bevacizumab [Avastin], Capecitabine, Irinotecan
- Where
- 44 sites in Italy
- Volunteers
- 306 people
- Sponsor
- Hoffmann-La Roche
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC)
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1…
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- Trial name
- NCT02649790
- Testing
- KPT-8602, ASTX727, Dexamethasone
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 277 people
- Sponsor
- Karyopharm Therapeutics Inc
Solid Tumors, Colorectal Cancer
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02632448
- Testing
- LY2880070, Gemcitabine
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 229 people
- Sponsor
- Esperas Pharma Inc.
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667)…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer
- Trial name
- ARROW (NCT03037385)
- Testing
- pralsetinib (BLU-667)
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 590 people
- Sponsor
- Hoffmann-La Roche
Metastatic Cancer, Melanoma
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
This is a pilot study designed to evaluate the cutaneous effect of systemic inhibition of the tyrosine kinase pathway in the presence or absence of solar simulated light exposure.
- Conditions
- Metastatic Cancer, Melanoma, Colon Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03176485
- Testing
- Solar Simulator
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Arizona
Metastatic Colorectal Adenocarcinoma
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Managements for refractory proficient mismatch repair (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) were still challenging and controversial.
- Trial name
- NCT05942768
- Testing
- regorafenib plus anti-PD-1 antibodies
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Hunan Cancer Hospital
Metastatic Breast Cancer, Pancreatic Cancer
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Capecitabine in Patients with Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic…
- Conditions
- Metastatic Breast Cancer, Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT02210364
- Testing
- lurbinectedin (PM01183), capecitabine
- Where
- 2 sites in Belgium, Spain
- Volunteers
- 81 people
- Sponsor
- PharmaMar
Metastatic Colorectal Cancer
Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer
A growing amount of reports has consistently evidenced that a sustained inhibition of the angiogenesis is an effective therapeutic strategy, able to improve the outcome of metastatic colorectal cancer (mCRC) patients.
- Trial name
- CIRCUS (NCT02623621)
- Testing
- chemotherapy plus bevacizumab
- Where
- Italy
- Volunteers
- 103 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.